Pfizer Inc PFE

$29.23 -0.16 (-0.54%)

Valuation

Market cap
167,518,704,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
P/E (trailing)
9.80
P/E (forward)
9.87
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
45,770,000
Avg volume
33,988,637
Day's range
$28.98 – $29.63
Shares out
5,699,854,000
Stochastic %K
24%
Beta
0.31
Analysts
Hold
Price target
$30.35

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

RallyRocket Nov 10, 9:24 AM
$ONDS $PFE gem``
0 replies
A_Train1 Nov 10, 4:21 AM
$PFE I think I finally figured out this stock. It has to stay at its current price for that number of days before it can move up to the next dollar. So, right now we’re in the 29’s. Ergo, it takes 29 days in the $29.xx range in order to move to $30’s. Mark it!
0 replies
Stocktradesmoon Nov 10, 2:15 AM
$ABCL $HIMS $IAM $REGN $PFE $ABCL could be valued today at $15-20B given its accomplishments + potential. It would be a rich valuation and would take some time before it grew into such a mkt cap and then beyond, but it could definitely be supported in today’s market. Instead, it trades at $4B. $30+ stock!!
0 replies
RallyRocket Nov 10, 12:45 AM 0 replies
Stocktradesmoon Nov 10, 12:40 AM
$ABCL $HIMS $MRNA $SLS $PFE ABCellera 🔥 🔥!!! 👑
0 replies
Stocktradesmoon Nov 9, 11:35 PM
$ABCL $REGN $SLS $PFE $MRNA ABSOLUTELY 💯 ABcellera🔥 🔥!!!
0 replies
RallyRocket Nov 9, 11:07 PM
$PFE $BAC 🤎
0 replies
Stocktradesmoon Nov 9, 11:04 PM
$ABCL $IAM $REGN $MRNA $PFE Long-term $ABCL holder. 7 internal drug programmes, ABCL635 heading towards Phase 3, and $890M+ in available liquidity. Futures bright.
0 replies